无创肝纤维化检测在慢性乙型肝炎抗肝纤维化治疗中的应用价值

Value of noninvasive detection in Anti-hepatic fibrosis therapy of chronic hepatitis B

目的探讨无创肝纤维化检测在慢性乙型肝炎抗肝纤维化治疗中的应用价值。方法选择2016年10月~2017年10月在我院诊治的慢性乙型肝炎患者825例,按照随机数字法分为两组,治疗组412例患者采用恩替卡韦与扶正化瘀胶囊治疗,对照组413例患者单用恩替卡韦治疗,并采用无创肝纤维化检测,以观察两组治疗的临床效果。结果治疗前,两组患者的肝功能、肝脏硬度值、脂肪衰减数水平比较,差异无明显统计学意义(P>0.05)。治疗后,两组患者的脂肪衰减数值无明显差异(P>0.05),但治疗组的肝功能、肝脏硬度值均较对照组明显改善,差异均有统计学意义(P<0.05)。结论慢性乙型肝炎患者采用恩替卡韦与扶正化瘀胶囊抗肝纤维化治疗的效果显著,同时采取无创肝纤维化检测动态评估抗肝纤维化治疗效果,为临床大样本、长期观察慢性乙型肝炎肝纤维化的转归提供了一种有着良好应用前景的检测方法。

Objective To explore the value of noninvasive detection of hepatic fibrosis in the treatment of chronic hepatitis B with anti-hepatic fibrosis therapy. Methods Choice 825 cases of patients with chronic hepatitis B from October 2016 to October 2017 in our hospital divided into two groups according to random number method.The treatment of 412 cases of study group was used the entecavir and Fu Zheng Hua Yi capsule,and 413 cases of control group was used the entecavir only,and observe the clinical effect of two groups with noninvasive detection of liver fibrosis. Results Before the treatment,the liver function,liver hardness value,and the amount of fat attenuation level in patients of two groups,there was no statistical difference（P〉0.05）.After treatment,no obvious difference was found between two groups of patients with fatty attenuation value（P〉0.05）,but the liver function and liver hardness value in study group were obviously improved than the control group（P〈0.05）. Conclusion The effect of anti-hepatic fibrosis therapy with entecavir and Fu Zheng Hua Yi capsule in patients with chronic hepatitis B is significantly.At the same time,take the noninvasive detection of liver fibrosis is dynamic assess the treatment effect of liver fibrosis,and provide a detection method for clinical observe the chronic hepatitis B liver fibrosis of large sample and long-term outcome.